Key facts
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
|---|---|
| Manufacturer | Breckenridge Pharmaceutical, Inc. |
| Brand name | DULOXETINE |
| Product description | Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. |
| Classification | Class II |
| Recall number | D-0583-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |
What this classification means
FDA classifies a recall as Class II when using the recalled product, or being exposed to it, may cause temporary or medically reversible adverse health consequences, or when the probability of serious adverse health consequences is remote. In this case, the recalling firm is Breckenridge Pharmaceutical, Inc. and the affected product is described in FDA's record as: Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ (additional items listed in FDA's full record). FDA's stated reason for the recall is: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. The recall is tracked under FDA recall number D-0583-2026 and carries a status of Ongoing as of the most recent FDA enforcement report. This classification reflects FDA's assessment of the product defect described above, not a prediction about any specific patient outcome. FDA maintains a public enforcement report database so that consumers, physicians, and purchasers can look up the exact product identifiers involved before deciding what to do. Recall status can change while FDA and the recalling firm continue corrective actions, so checking the firm's own notice for the most current guidance is recommended.
What consumers should do
Because this recall carries FDA's middle severity classification, anyone who has this product should stop using it and follow the recalling firm's instructions, even though serious harm is considered unlikely for this classification. Specifically, check whether the product in your possession matches the description on file with FDA -- Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ (additional items listed in FDA's full record) -- and the recall number D-0583-2026. If it matches, stop using or distributing it and contact Breckenridge Pharmaceutical, Inc. or the point of purchase for return or replacement instructions. Retailers and distributors holding affected inventory should quarantine it and follow the firm's written recall notice.
Breckenridge Pharmaceutical, Inc.’s FDA history
Argus HQ has recorded 3 total FDA actions tied to Breckenridge Pharmaceutical, Inc.: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- How serious is this recall?
- FDA classifies a recall as Class II when using the recalled product, or being exposed to it, may cause temporary or medically reversible adverse health consequences, or when the probability of serious adverse health consequences is remote.
- What should someone who has this product do?
- Because this recall carries FDA's middle severity classification, anyone who has this product should stop using it and follow the recalling firm's instructions, even though serious harm is considered unlikely for this classification. Check the product against FDA's description (Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ (additional items listed in FDA's full record)) and recall number.
- Has Breckenridge Pharmaceutical, Inc. had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 3 total FDA actions tied to Breckenridge Pharmaceutical, Inc., including 3 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number D-0583-2026.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Breckenridge Pharmaceutical, Inc.Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Recall Database: Class II Recall: DULOXETINE by Breckenridge Pharmaceutical, Inc.. Digital Empire LLC. Retrieved from https://argushq.ai/recall/fda-recall-breckenridge-pharmaceutical-inc-d-0583-2026
"FDA Recall Database: Class II Recall: DULOXETINE by Breckenridge Pharmaceutical, Inc.." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/recall/fda-recall-breckenridge-pharmaceutical-inc-d-0583-2026.
Argus HQ Research. "FDA Recall Database: Class II Recall: DULOXETINE by Breckenridge Pharmaceutical, Inc.." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/recall/fda-recall-breckenridge-pharmaceutical-inc-d-0583-2026.
@misc{argushq_argushq_ai_recall_fda_recall_breckenridge_pharmaceutical_inc_d_0583_2026_2026,
title = {FDA Recall Database: Class II Recall: DULOXETINE by Breckenridge Pharmaceutical, Inc.},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/recall/fda-recall-breckenridge-pharmaceutical-inc-d-0583-2026},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Recalls ↗

